Natural product drug discovery: The successful optimization of ISP-1 and halichondrin B

Current Opinion in Chemical Biology

Volumn 15, Issue 4, 2011, Pages 523-528

  Yeung, Bryan KS ^a  

^a Novartis Institute for Tropical Diseases   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ERIBULIN; FINGOLIMOD; HALICHONDRIN B; ISP 1; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG QUALITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IN VITRO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL AGENTS; DRUG DISCOVERY; ETHERS, CYCLIC; FATTY ACIDS, MONOUNSATURATED; FURANS; KETONES; MOLECULAR STRUCTURE; PROPYLENE GLYCOLS; SPHINGOSINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79961010756     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2011.05.019     Document Type: Article

References (25)

1. Adachi K., Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Med Chem 2007, 1:11-23.
2. Jackson K.L., Henderson J.A., Phillips A.J. The halichondrins and E7389. Chem Rev 2009, 109:3044-3079.
3. Borel J.F., Feurer C., Magnée C., Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977, 32:1017-1025.
4. Fujita T., Yoneta M., Hirose R., Sasaki S., Inoue K., Kiuchi M., Hirase S., Adachi K., Arita M., Chiba K. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity. Bioorg Med Chem Lett 1995, 5:847-852.
5. Fujita T., Hamamichi N., Kiuchi M., Matsuzaki T., Kitao Y., Inoue K., Hirose R., Yoneta M., Sasaki S., Chiba K. Determination of absolute configuration and biological activity of new immunosuppressants, mycestericins D, E, F, and G. J Antibiot 1996, 49:846-853.
6. Adachi K., Kohara T., Nakao N., Arita M., Chiba K., Mishina T., Sasaki S., Fujita T. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3 propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995, 5:853-856.
7. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., Chiba K. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005, 2:439-448.
8. Miyake Y., Kozutsumi Y., Nakamura S., Fujita T., Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995, 211:396-403.
9. Kiuchi M., Adachi K., Kohara T., Minoguchi M., Hanano T., Aoki Y., Mishina T., Arita M., Nakao N., Ohtsuki M., et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem 2000, 43:2946-2961.
10. Fujita T., Hirose R., Yoneta M., Sasaki S., Inoue K., Kiuchi M., Hirase S., Chiba K., Sakamoto H., Arita M. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J Med Chem 1996, 39:4451-4459.
11. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
12. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003, 554:189-193.
13. Brinkmann V., Lynch K.R. FTY720: targeting G-proteincoupled receptors for sphingosine 1 phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002, 14:569-575.
14. Albert R., Hinterding K., Brinkmann V., Guerini D., Müller-Hartwieg C., Knecht H., Simeon C., Streiff M., Wagner T., Welzenbach K., et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J Med Chem 2005, 48:5373-5377.
15. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
16. Hirata Y., Uemura D. Halichondrins-antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986, 58:701-7190.
17. Bai R., Paull K.D., Herald C.L., Malspeis L., Pettit G.R., Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. J Biol Chem 1991, 266:15882-15889.
18. Munro M.H.G., Blunt J.W., Dumdei E.J., Hickford S.J.H., Lill R.E., Li S., Battershill C.N., Duckworth A.R. The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol 1999, 70:15-25.
19. Aicher T.D., Buszek K.R., Fang F.G., Forsyth C.J., Jung S.H., Kishi Y., Matelich M.C., Scola P.M., Spero D.M., Yoon S.K. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992, 114:3162-3164.
20. Jackson K.L., Henderson J.A., Motoyoshi H., Phillips A.J. A total synthesis of norhalichondrin B. Angew Chem Int Ed 2009, 48:2346-2350.
21. Seletsky B.M., Wang Y., Hawkins L.D., Palme M.H., Habgood G.J., DiPietro L.V., Towle M.J., Salvato K.A., Wels B.F., Aalfs K.K., et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg Med Chem Lett 2004, 14:5547-5550.
22. Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., Littlefield B.A., Wilson L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005, 4:1086-1095.
23. Verdier-Pinard P., Bai R., Yu M.J., Littlefield B.A., Hamel E. Interaction of ER-086526, a new synthetic halichondrin B analog, with tubulin. Mol Biol Cell 2000, 11:Suppl 188a.
24. Kamath K., Okouneva T., Miller H., Davis C., Littlefield B.A., Wilson L., Jordan M.A. E7389, a synthetic analog of halichondrin B, suppresses microtubule dynamics in living MCF7 cells by a novel mechanism. Proc Am Assoc Cancer Res 2003, 44. Abs LM-43.
25. Dabydeen D.A., Burnett J.C., Bai R.L., Verdier-Pinard P., Hickford S.J.H., Pettit G.R., Blunt J.W., Munro M.H.G., Gussio R., Hamel E. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006, 70:1866-1875.